Skip to main
MDT
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 41 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 39%
Sell 0%
Strong Sell 2%

Bulls say

Medtronic's strong performance in the neuromodulation and diabetes sectors, highlighted by a 240 basis point increase in market share and mid-single-digit revenue growth, indicates robust demand and successful product adoption, particularly with the MiniMed 780G AID system. The company's positive revenue outlook for FY25, estimated to rise by 3.4-3.8%, along with an EPS guidance reflecting a 10-11% annual growth rate (excluding currency effects), showcases its financial health and capacity for profitability. Additionally, improvements in non-GAAP gross and operating margins, driven partly by favorable currency effects, complement Medtronic's potential for enhanced market share in the cardiac ablation space, further supporting a bullish outlook on its stock.

Bears say

Medtronic's stock outlook is negatively affected by anticipated revenue growth slowing to low-single digits due to unsuccessful new product launches and market share losses in certain categories, alongside flat or declining operating margins that could result in below-consensus earnings. Additionally, the company faces risks from competitive product introductions, disappointing sales from promising new technologies, and a projected 5% unfavorable impact from foreign exchange on earnings per share in FY25. The recent decline in organic growth, which fell to 4.1% in the most recent quarter, further underscores the challenges posed by distributor destocking negatively impacting the Medical Surgical segment.

Medtronic (MDT) has been analyzed by 41 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 39% suggest Holding, 0% advise Selling, and 2% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 41 analysts, Medtronic (MDT) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.